ESMO 2016 Congress:
ESMO announces press programme presenting latest cancer research
Lugano/Copenhagen, 22 September 2016. Breaking news on innovative cancer treatments will be announced at ESMO 2016, the annual oncology congress organised by the European Society for Medical Oncology, taking place from 7 to 11 October 2016 at Bella Centre in Copenhagen, Denmark.
Register now(http://esmo.formstack.com/forms/media_registration_form_esmo2016) for ESMO 2016 and be the first to hear the results of highly anticipated trials such as:
- EORTC 18071 for stage III melanoma
- ENGOT-OV16/NOVA, a landmark trial for ovarian cancer
- KEYNOTE 024 for advanced non-small cell lung cancer
- MONALEESA 2 study for advanced breast cancer
This is just a small taste of the science that will be presented in this year’s late breaking trials.
Three press conferences will allow journalists to discuss the new treatments directly with principal investigators. Press releases will cover late breaking trials but also other important topics such as adherence to treatment, screening for cancer and timely access to cancer drugs. Find the press conference programme here: http://esmo.org/Conferences/ESMO-2016-Congress/Press-Media/Press-Conference-Programme
Additional hot topics will be presented in special sessions. See the Scientific Programme Online here:http://www.esmo.org/Conferences/ESMO-2016-Congress/Programme
Recommendations from Track Chairpersons can be found here:http://www.esmo.org/Conferences/ESMO-2016-Congress/Programme/Track-Chairs-Top-Picks
There will also be a Patient Advocacy Track for both patient advocates and doctors covering topics such as patients driving research, management of side-effects and debunking cancer myths.
Public policy sessions will focus on important issues including equitable access to anti-cancer drugs, cancer registries, use of Big Data, personalised medicine and different approaches to measuring the clinical benefit of cancer drugs.
Despite advances made in diagnosis and treatment over the last 20 years, cancer is still the second leading cause of death worldwide and becoming number one in at least 12 European countries (1). Much remains to be done to ensure equal and timely access to treatment and care.
The ESMO 2016 Congress will bring good news for cancer patients by showcasing the latest available treatments. Nearly 2,900 abstracts (including over 80 late-breaking studies) were submitted for inclusion in the ESMO 2016 Congress programme, marking a 70% increase over the past six years and confirming the ESMO Congress as the leading oncology event in Europe. Overall, 1,661 abstracts will be presented at ESMO 2016. Abstract titles and authors are now online. Top submissions were in colorectal and gastrointestinal cancers, non-small-cell lung cancer, genitourinary tumours and immunotherapy.
With USA, Italy, Spain, France and Japan being the top five submitters, the ESMO 2016 Congress will be a truly international convention, where you can learn about the latest advances in cancer, discuss clinical challenges and share best practices in order to improve patient treatment and care.
More than 19,000 participants from 130 countries worldwide are expected in Copenhagen, ranging from professionals representing various oncology disciplines to healthcare policy makers, from patient advocates and pharmaceutical companies to international media.
Notes to editors
Media registrationhttp://esmo.formstack.com/forms/media_registration_form_esmo2016
ESMO welcomes media interested in obtaining information and reporting on cancer issues. Registration is free to bona fide journalists on presentation of a letter of assignment and a valid press card.
Media representatives are required to observe and abide by the ESMO 2016 Media Policy (http://www.esmo.org/Conferences/ESMO-2016-Congress/Press-Media/Media-Policy)
To register for the event, please fill out the Complimentary Media Registration Form here:http://esmo.formstack.com/forms/media_registration_form_esmo2016
Media registration in advance is strongly recommended (deadline:Thursday, 29 September 2016).
A fully equipped ESMO Press Centre will be available to registered journalists, including a press room with technical facilities (computers, wi-fi, etc.), interview rooms and storage cabinets. On-site staff will be ready to assist and facilitate one-on-one interviews with researchers and key opinion leaders throughout the Congress.
ESMO Press Programme
The official ESMO 2016 Press Programme can be found here:
http://esmo.org/Conferences/ESMO-2016-Congress/Press-Media/Press-Conference-Programme
Meeting venue and accommodation
The ESMO 2016 Congress will take place at the Bella Center Copenhagen, in the heart of Ørestad with its own Metro station (M1). Bella Center Copenhagen is conveniently located for both Copenhagen Airport (six kilometres) and Copenhagen city centre (eight kilometres).
BELLA CENTER COPENHAGEN
Center Boulevard 5
DK – 2300 Copenhagen S
Embargo information:
- Abstracts accepted for presentation at ESMO 2016 as Poster Discussion and Poster will be published online on the ESMO website at 12:00 CEST (local Swiss time) on Wednesday, 28 September 2016.
- Abstracts accepted for presentation at ESMO 2016 as Proffered Paper (oral presentation) will be published online on the ESMO website at 12:00 CEST (local Swiss time) on Wednesday, 05 October 2016.
- Late-breaking abstracts will be made public at 08:15 CEST (local Swiss time) on the day of the official Congress session during which they are presented.
- Abstracts selected for the official ESMO Press Programme will be made public at the beginning of the official Press Conference during which they are presented at 08:15 or 12:30 CEST (local Swiss time).
The ESMO Press Office Team
Tel: +41 (0)91 973 19 04 (until 4 October)
Tel: +45 8177 2926 (from 5 October)
Tel: +45 8177 2922 (from 5 October)
References
(1) Cancer in OECD countries: http://www.oecd- ilibrary.org/docserver/download/8115071ec009.pdf?expires=1473164141&id=id&accname=guest&checksum=485C9A4DBAEEAD0391A6FDD2B4644E1E
Resources
WHO key facts about cancer:http://www.who.int/mediacentre/factsheets/fs297/en/
WHO Globocan statistics on cancer worldwide:
http://globocan.iarc.fr/Pages/fact_sheets_cancer.aspx
WHO Globocan statistics on cancer in Europe: